NeoGenomics secured a summary judgement invalidating key patents asserted by rival Natera, lifting an injunction that had halted commercialization of its Radar minimal residual disease (MRD) assay. The decision clears the path for NeoGenomics to advance Radar ST, an upgraded solid tumor assay, initially targeting breast and head and neck cancers. The patent victory significantly reduces legal barriers and expenses, bolstering NeoGenomics' competitive positioning in the growing MRD testing market, crucial for cancer relapse monitoring and precision oncology.